Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(29 sites)

United States

Research Site, Decatur, Illinois

Research Site, New York, New York

Research Site, Durham, North Carolina

Research Site, Portland, Oregon

Research Site, Houston, Texas